REG - Beximco Pharma. - Annual General Meeting Statement

Beximco PharmaceuticalsAnnouncement

30/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241230:nRSd5683Ra&default-theme=true

RNS Number : 5683R  Beximco Pharmaceuticals Ltd  30 December 2024

30 December 2024

 

BEXIMCO PHARMACEUTICALS LIMITED

 

Annual General Meeting Statement

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM
Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical ingredients, today
announces that all resolutions put before shareholders at the Company's Annual
General Meeting ("AGM") held virtually on 29 December 2024 were duly passed.

 

The resolutions passed at the AGM included the approval of 40% cash dividend
for the year ended on 30 June 2024. The cash dividend being 40% of the nominal
value per ordinary share of Taka 10 (Taka 4.0 per ordinary share/per global
depository receipt ("GDR") held in respect of GDR holders) will be paid to
holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR
holders' as on the date of record, i.e. 25 November 2024) on or before 28
January 2025. The cash dividend will be paid after deduction of taxes as per
Bangladesh Tax law.

 

Additionally, the Special Resolution to change the name of the Company from
"Beximco Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC." as per the
provision of the Companies Act, 1994 (as amended in 2020) and to effect the
change of the name in the relevant Clauses of the Memorandum and Articles of
Association of the Company was passed. Further announcements will be made in
due course when the name change will come into effect.

 

The Annual Report for 2023-24 is available from the Company's website, which
includes the audited accounts and a review of operations for the year ended on
30 June 2024.

 

For further information please visit www.beximcopharma.com
(http://www.beximcopharma.com/)  or enquire to:

 

 Beximco Pharma
 S M Rabbur Reza, Chief Operating Officer

 Tel: +880 2 58611001, Ext. 20111

 Mohammad Ali Nawaz, Chief Financial Officer

 Tel: +880 2 58611001, Ext. 20030

 Mohammad Asad Ullah, FCS

 Executive Director & Company Secretary

 Tel: +880 2 41060531, Ext. 10140

 SPARK Advisory Partners Limited (Nominated Adviser)

 Mark Brady / Andrew Emmott

 Tel: +44 (0)20 3368 3551 / 3555

 SP Angel Corporate Finance LLP (Broker)

 Matthew Johnson

 Tel: +44 (0) 20 3470 0470

 FTI Consulting

 Simon Conway / Victoria Foster Mitchell / Sam Purewal

 Tel: +44 (0)20 3727 1000

 

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 6000 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the region.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMKZMZZGLNGDZZ